Developing countries could exploit traditional medicine to kick-start biotech, but only if their products measure up to the demands of Western regulators. Paroma Basu reports.
This is a preview of subscription content, log in via an institution to check access.
References
World Health Organization Secretariat. Traditional Medicine (WHO, Fifty-Sixth World Health Assembly, A56/18, March 31, 2003) (http://www.who.int/gb/EB_WHA/PDF/WHA56/ea5618.pdf).
Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry Botanical Drug Products. Fed. Register 65, 49247–49248, 2000. (http://www.fda.gov/cder/guidance/1221dft.pdf).
European Parliament. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. (Official J. Eur. Commun., L311, 67–128, 2001. (http://europa.eu.int/eur-lex/pri/en/oj/dat/2001/l_311/l_31120011128en00670128.pdf).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Basu, P. Trading on traditional medicines. Nat Biotechnol 22, 263–265 (2004). https://doi.org/10.1038/nbt0304-263
Issue Date:
DOI: https://doi.org/10.1038/nbt0304-263
- Springer Nature America, Inc.
This article is cited by
-
Continuous cropping of endangered therapeutic plants via electron beam soil-treatment and neutron tomography
Scientific Reports (2018)
-
Gibberella moniliformis AH13 with Antitumor Activity, an Endophytic Fungus Strain Producing Triolein Isolated from Adlay (Coix lacryma-jobi: Poaceae)
Current Microbiology (2014)
-
The road to commercialization in Africa: lessons from developing the sickle-cell drug Niprisan
BMC International Health and Human Rights (2010)
-
Opportunities and Challenges in Antiparasitic Drug Discovery
Nature Reviews Drug Discovery (2005)
-
Can China bring its own pipeline to the market?
Nature Biotechnology (2004)